12th Congress of the European Hematology ... - Haematologica

More documents

Recommendations

Info

12 th Congress of the European Hematology Association Amorim, A., 0025 Amoyuel, P., 0474 Amrein, K., 0836 Anaclerico, B., 0991 Anagnostopoulos, A., 1264, 1458, 1534 Anagnostopoulos, G., 0809, 1328 Anagnostopoulos, N., 1289 Anargyrou, K., 0117, 0179, 0393, 0685, 0885, 1186 Anastasi, G., 0036 Anastasiadis, A., 0630, 0992 Ancliff, P., 0876 And the German CML Study Group, Germany, 0441 Anderlini, P., 0500 Andersen, B.L., 0571 Anderson, K.C., 0258, 0269, 0312, 0689 Andjelic, B., 1072 Andolfo, I., 1221 Andrade, C., 1131 Andrade, J., 0664 Andrè, V., 0877 Andre Botté, C., 0464 Andreasson, B., 0412 Andreeff, M., 0651, 0747 Andreini, A., 0713, 0721, 0583 Andreola, G., 1292 Andres, E., 1317, 1335 Andrieu, V., 1093 Andrieux, J., 0690 Andrikovics, H., 0083, 1026 Andrys, C., 0669, 0949, 1338 Andrzej, A.H., 0491 Andrzejak, R., 1288 Anelli, L., 0539 Anemona, L., 1187 Ang, A.L., 0971 Angastiniotis, M., 0798 Angelini, S., 0536, 0696 Angell, J., 1346 Angelopoulos, N., 0809, 1328 Angelopoulou, M., 0117, 0179, 0287, 0393, 0685, 0714, 0885, 1186, 1256, 1377 Angelova, S., 1452 Angelucci, E., 0408, 0423 Annaloro, C., 0205 Annetta, I., 0703, 1422 Annino, L., 0991 Annunziata, M., 0051, 0765 Antevska-Trajkova, Z., 1150 Antic, D., 1361 Antignano, A., 1226 Antmen, B., 1258, 1270 Antonakis, G., 1466 Antonelli, C., 0351 Antonelou, M., 1143 Antoniadis, A., 0179 Antoniadou, L., 0914 Antonio, M., 0650 Antonio Franceschini, S., 1114 Antonioli, E., 0645, 0667, 0896, 0897, 1284 Antoniotti, P., 0843 Antonowicz-Juchniewicz, J., 1288 Antonuccio, E., 1183 Apanovitch, A.M., 0026 Apostolakou, F., 0806 Apperley, J., 0358, 0498, 0456, 0527, 0541, 0543, 0544, 0599, 0686 Appleby, N., 0816 Appleton, C., 0434 b | haematologica/the hematology journal | 2007; 92(s1) Aquino, S., 0177, 1180, 1538 Arancha, R.C., 0206 Aranha, F.J.P., 1181 Aras, D., 1318 Arat, M., 0052, 1058, 1353, 1447, 1509 Araujo, A.G., 0944 Arcaini, L., 0647, 0649, 0716, 0729, 0730 Arcese, W., 0452, 0616, 1381 Arcioni, F., 0138 Ardaiz, M., 0307 Ardaiz, M.A., 0090, 1151, 1324 Ardanaz, M., 1137 Ardern, J., 0775 Aref, S., 1336 Arellanes-Robledo, J., 1212 Arenillas, L., 1137 Arghirescu, S., 0086, 0725 Argiropoulos, B., 0872 Arguiñano, J.M., 0090, 1151, 1324 Arias, M.A., 0829 Ariola, C., 0013 Arkin, M.R., 0489 Arlotto, M., 0159, 0166 Armellini, A., 0174, 0699, 0700 Armstrong, S.A., 0045 Arnaud, P., 0617 Arning, M., 0390, 0758, 0760, 0761 Arnold, R., 0027, 0374 Arnoulet, C., 0908, 1047 Aroutiounian, R., 0955 Arranz, R., 0728 Arrazi, J., 0318 Arrossagaray, G., 0103 Arruga, F., 0044, 0156, 0198, 0199, 0636, 0665 Arslan, O.A., 1447 Artells, R., 0921 Artiko, V., 0753 Asaka, M., 0531, 1243, 1341 Asfour, I., 1432, 1546 Ashcroft, A.J., 0607 Ashraf, H., 1406 Ashur-Fabian, O., 1435 Asimaki, A., 1458 Aslan, V., 1172 Asnafi, V., 0873 Assmus, K., 0148 Astolfi, M., 0883 Astori, C., 0626 Astrelina, T., 1223, 1411 Atac, B., 0342, 0344, 0345 Atadja, P., 0153 Atalar, F., 0154, 0155, 0173, 1095 Atanackovic, D., 0584 Atasoy, B., 1092 Atay, A.A., 0088, 0819, 1155 Atayan, Y., 1219, 1491 Atchison, C., 0602 Athanasiadou, A., 1534 Athanasiadou, I., 1534 Athanassiadou, A., 0200 Athanassiou-Metaxa, M., 0803 Atkinson, M., 0037 Atmakusuma, T.D., 1281 Atsaves, V., 0290 Atta, R.I., 1478 Attal, M., 0264, 0265, 0266, 0267 Attalla, S., 1415 Attanoos, R., 1001 Attia, F., 1514 Auclerc, M.F., 0373 Audhuy, B., 0115 Auerbach, A., 0436 Aujay, A.N., 0739 Aul, C., 0234 Aureli, V., 0849 Aurer, I., 0622, 0687, 0967 Aurias, A., 0383 Aurrand-Lions, M., 0918 Ausenda, S., 0779, 0780 Austen, B., 0096 Auvrignon, A., 0373 Avanzi, M.P., 1463 Avci, Z., 0342, 0345 Avcu, F., 1155, 1376 Ave, E., 1024 Avent, N., 0915 Aventin, A., 0138 Avetisyan, G., 0955 Avgitidou, A., 1132, 1273, 1547 Avigdor, A., 0391, 0431 Avila, G., 0307 Avivar, C., 0781, 1285, 1321 Avonto, I., 0258, 0401, 0883 Avramakis, A.G., 1374 Awodu, O., 1519 Axdorph, U., 0061 Ay, C., 0347, 0574, 0878, 0879, 0880 Ayaz, S., 1318 Aydin, H.I., 0819 Aydinok, Y., 1295 Aydogan, B., 1270 Aytac, S., 1012 Ayuk, A., 0587 Ayyildiz, O., 0637, 0937, 1219, 1402 Azab, S., 1535 Azap, A., 1058 Azevedo, A., 1194 Azevedo, J., 0788, 0793, 1160 Azevedo, O., 1215 Azlarova, A., 1427 Azmy, E., 1336 Azoulay, E., 0216 Azzalin, A., 0218 Azzaro, M.P., 0824, 0826 Azzarone, B., 0517 B Babadoko, A., 0081 Babicka, L., 0131, 0134, 0968 Baccarani, M., 0006, 0140, 0496, 0536, 0549, 0550, 0555, 0556, 0559, 0561, 0562, 0569, 0601, 0662, 0696, 0745, 0906 Bacchu, S., 0619 Bacci, F., 0385 Bacigalupo, A., 0049, 0076, 0389, 0424, 0438, 0468, 0724 Bacovsky, J., 0133, 1113, 1266 Badea, D., 0682, 1066 Badea, M., 0682, 1066 Bader, P., 0367 Bae, K., 0954 Bae, S.-H., 1530 Baer, R., 1027 Baerlocher, G.M., 0522 Baesso, I., 0278, 1024 Baggio, M.S., 0477 Bagnasco, F., 0076 Bahadir, N., 1257
Bahr, J., 0148 Bai, M., 1551 Baia, M., 0722 Baica, M., 0725 Baidildina, D., 1098 Baiget, M., 0781 Bailén, A., 1340 Bairamgulov, R.R., 1439 Bairey, O., 0715 Bajpai, P., 0529 Bakanay, S., 1353 Bakrac, M., 0683, 1069, 1104 Bakun, A., 0523 Balagué, O., 0706, 0921 Balamtekin, N., 0088 Balanzategui, A., 0174, 0699, 0700 Balatzenko, G., 1267, 1452 Balbi, G., 0468 Balcarkova, J., 0133 Balcerska, A., 0071 Balcik, Ö., 1522 Baldazzi, C., 0140 Baldini, L, 0697, 0973 Balducci, D., 0057, 0895 Balea, M.I., 1204, 1315, 1481 Balea, M.L.A., 1204, 1315, 1481 Baliva, G., 1187 Balkan, C., 1295 Balkanova Krstevska, S., 1373 Balleari, E., 0049, 0177, 0517 Ballerini, F., 0177, 1180 Ballesteros, M., 1286 Ballove, V., 0717 Balmer, P., 0211 Balocco, M., 0177, 1180 Balwierz, W., 0071 Balzarotti, M., 0867 Bambach, I., 0295, 0920 Bambi, F., 1446 Bamihas, G., 1458 Bañas Llanos, M.H., 1287, 1520 Banat, A.G.B, 0308 Bandini, G., 1039 Bandrés, E., 0097, 0869 Banelli, B., 0152 Bang, S.M., 0300 Banti, A., 0079, 0657 Bar, I., 0448 Bar Cohen, S., 0054 Baranger, L., 0467, 1011 Baranwal, A., 0761 Barba, G., 0139 Barbany, G., 0367 Barbarat, A., 0166 Barbarroja, N., 0163, 0469 Barbas III, C., 0200 Barberi, A., 1226 Barbieri, E., 0538 Barbon, M., 1137 Barbot, J., 0161, 0783, 0786 Barbu, R., 1424 Barbui, T., 0057, 0245, 0423, 0562, 0645, 0895, 1127, Barcellini, W., 0623 Barcena Carrasco, P., 0206 Bardet, V., 0040, 0323 Bardi, A., 0107 Barez, A., 0680, 0748 Bargay, J., 0404 Barghout, V., 0560 Bari, A., 0709 Barila, D., 0689 Barillari, G., 0092 Barin, C., 0467, 0887, 0922 Baringo, T., 1136, 1548 Barkatz, C., 1097 Barlati, S., 0633 Barnet, M., 0918 Baron, S., 0038, 0516 Baronci, C., 0750 Baronciani, L., 0091 Barosi, G., 0645, 0667 Barrans, S.L., 0135, 0137 Barreiro, G., 0305 Bartels, K., 0584 Bartlett, J.B., 0314, 0737 Bartley, P.A., 0567 Bartmann, C., 0846, 0854, 0855, 0857 Baruchel, A., 0373, 0383, 1100 Baryakh, E., 1216 Baryshnikov, A.Yu., 1015 Barzal, J.B., 1228 Basara, N. B., 0308 Basdiara, I., 0630 Baseggio, L., 0288, 0292, 0908 Basilico, C., 0205 Bassan, R., 0423, 0559 Bassi, S., 1057 Bassi, S., 0559, 0562 Bassiouny, M.R., 0960 Basso, A., 0307 Basso, D., 0892, 0973 Basso, G., 0020, 0024, 0152, 0169, 0888, 0891, 0892, Bastard, C., 0887, 0908, 1290 Bastit, L., 0768 Bátai, Á., 1261 Bataneant, M., 0086, 0725 Batinic, D., 0687 Batish, S.D., 0436 Batlle, M., 0461, 1199 Bátorfi, J., 0083 Battaglioli, T., 0341 Battista, M., 0458 Battmer, K., 0240 Baudis, M., 0170 Baudry-Bluteau, D., 0149 Baum, C., 0420, 0872 Baumann, A., 0410 Baumann, B., 1099 Bäumelt, V., 0774 Baumgartner, Ch., 0969 Bauters, A., 0354 Bauters, F., 0690 Bauters, M., 0442 Bautista, G., 0839 Bavaro, P., 0403 Baxevanos, G., 1198, 1309 Bay, J., 0425 Bayat, A.A., 0512 Baz, E., 1106 Bazarbachi, A., 0145, 0146, 0310, 0733, 0830, 1106, 1462, Bazdiara, I., 0992 Bazyka, D.A., 0037, 0964, 1019, 1101, 1122 Bazzeh, F., 0395, 1244 Beanceur, A.L., 0397 Bearz, A., 0726 Beatriz, B., 1475 12 th Congress of the European Hematology Association Bebeshko, V., 0037, 1101, 1451 Bebeshko, V.G., 1019, 1122 Becheanu, G., 1229 Beck, D., 0017 Becker, C., 0019, 1178 Bednárová, D., 0011 Bedoui, M., 1260, 1484 Beelen, D.W., 0858 Beer, P.A., 0241 Beggiato, E., 0756, 1191 Beghini, A., 1350 Begu, M., 1398 Beguin, Y., 0376 Behre, G., 0463 Behrens, B., 0368 Beishuizen, A., 0225 Beksac, M., 0052, 1092, 1353, 1447 Belada, D., 0125, 0949, 1087, 1449, 1501 Belfanti, A., 0612 Belhadjali, Z., 1149, 1247 Belisario Filho, V., 0418 Belkaci, M., 0128 Bell, L., 0380 Bellei, M., 0863 Bellesi, S., 0589, 0635, 0676, 0823 Bellis, L., 1299 Bellmann, R., 0214 Bellmann-Weiler, R., 0214 Bellosillo, B., 0304, 0646, 1070 Bellotti, D., 0633 Belmatoug, N., 0735 Belo, L., 0776, 0783, 0786, 0789, 1171 Beltrán-Ramírez, O., 1212 Belyaeva, N.V., 1019 Ben Amor, R., 1149, 1247 Ben Lakhal, R., 1149, 1247 Ben Moussa, F., 1260 Ben Othman, T., 0988, 1236 Benabid, H., 1149, 1247 Beñaran, B., 1438 Benatti, C., 0218, 0219 Benavente, C., 1391 Ben-Bassat, I., 0391 Bencur, P., 0347, 0574 Bendandi, M., 1179 Bendit, I., 0526, 1233 Bendit, M., 0526, 1233 Bene, L., 0279, 1425 Béné, M.C., 0601, 0891 Benecke, A., 0842 Benedetti, E., 0403 Benedetti, F., 0406, 0583, 0713, 0721 Benet Campos, C., 1550, 1314 Benetatos, L., 1081, 1399 Benites, B.D., 1061 Bennada, K, 0540, 1052 Bennani, J., 0109 Benner, A., 0099, 0297, 0298, 0694, 0909 Bennett, J.M., 0220 Bennett, M.K., 0739 Bensa, J.C., 0195 Bensoussan, D., 0464, 1189 Bentata, M., 0722 Bento, C., 0813, 1384 Ben-Yosef, R., 0187 Ben-Zion, K., 0038 Beran, M., 0072 Beranek, M., 0669, 1449, 1501 Berankova, J., 0451 Berenguer, J., 0727 haematologica/the hematology journal | 2007; 92(s1) | c
Page 1 and 2:
haematologica the hematology journa
Page 3 and 4:
Information for readers, authors an
Page 5 and 6:
EHA Executive Board E. Hellström-L
Page 7 and 8:
Poster session I POSTER SESSION POS
Page 9 and 10:
12 th Congress of the European Hema
Page 11 and 12:
dasatinib. Methods. We studied Ikar
Page 13 and 14:
Expression of the oncogene H-Ras an
Page 15 and 16:
is the gene for the erythropoietin
Page 17 and 18:
safety of a slow-release liposomal
Page 19 and 20:
0029 OUTCOME OF THE TREATMENT OF AD
Page 21 and 22:
drug-induced apoptotic response of
Page 23 and 24:
41% in the PI3K- group (p=0.001). I
Page 25 and 26:
Acute myeloid leukemia - Clinical I
Page 27 and 28:
to 60 years (n=116, or 72%) receive
Page 29 and 30:
0056 PROGNOSTIC SIGNIFICANCE OF FLT
Page 31 and 32:
Anemia and Bone marrow failure 0061
Page 33 and 34:
tified with the current protocol. S
Page 35 and 36:
new cases of lead poisoning due to
Page 37 and 38:
icance, from baseline to week 6 (p
Page 39 and 40:
0086 THROMBELASTOGRAPHIC CHART RELI
Page 41 and 42:
trials. The aim of this retrospecti
Page 43 and 44:
tant function in this disease, nega
Page 45 and 46:
ed to a favorable outcome. Bialleli
Page 47 and 48:
stronger levels of p21 in the cell
Page 49 and 50:
hematological centers in one countr
Page 51 and 52:
ure 1). Conclusions. Results for re
Page 53 and 54:
patients. After a median follow-up
Page 55 and 56:
Cytogenetics and Molecular diagnost
Page 57 and 58:
0135 ROUTINE DETECTION OF CYTOGENET
Page 59 and 60:
(MMolR, defined as a BCR-ABL x 100
Page 61 and 62:
0146 ARSENIC TRIOXIDE INDUCES ACCUM
Page 63 and 64:
tinguish between genotypic B-cell l
Page 65 and 66:
Genomics and proteomics 0158 PLASMA
Page 67 and 68:
0164 EVALUATION OF MULTIPLEX LIGATI
Page 69 and 70:
each patient’s replicate conditio
Page 71 and 72:
0174 RELATION BETWEEN LOW PML-RARα
Page 73 and 74:
0179 ESHAP VS GIN AS SALVAGE AND MO
Page 75 and 76:
Immunology and gene therapy 0184 EA
Page 77 and 78:
Cell viability was not affected by
Page 79 and 80:
month is not relevant to chronic Gv
Page 81 and 82:
Infection and supportive care I 020
Page 83 and 84:
0206 POTENTIAL ROLE OF CMV IN THE O
Page 85 and 86:
3H-thymidine uptake in cell culture
Page 87 and 88:
0217 TUBERCULOSIS AMONG A COHORT OF
Page 89 and 90:
0222 COMPARISON OF IWG 2006 AND IWG
Page 91 and 92:
tem (IPSS) to h-MDS was also invest
Page 93 and 94:
PCH97-19) were studied. Conventiona
Page 95 and 96:
of erythroid colonies was reduced i
Page 97 and 98:
0245 POTENT AND SELECTIVE INHIBITIO
Page 99 and 100:
0250 INACTIVATION OF SUPPRESSOR OF
Page 101 and 102:
Bortezomib 1.3 mg/m 2 days 1,4,8,11
Page 103 and 104:
Response was defined according to E
Page 105 and 106:
G-CSF can be used in neutropenic pa
Page 107 and 108:
ence and functional activity of CD8
Page 109 and 110:
itating tumor development, or engag
Page 111 and 112:
phoma and SNT-13, -15 were establis
Page 113 and 114:
usage (2/20 ie 10%) were observed.
Page 115 and 116:
0294 MYCOSIS FUNGOIDES. IMMUNOHYSTO
Page 117 and 118:
(range, 1-6) and 11 treatment cycle
Page 119 and 120:
0306 RISK-ADAPTED IMMUNOCHEMOTHERAP
Page 121 and 122:
functional activity was confirmed b
Page 123 and 124:
No major toxicity, neither hematolo
Page 125 and 126:
enewal potential of X-RAR-positive
Page 127 and 128:
(50-99) respectively. Serial analys
Page 129 and 130:
cell-interaction, adhesion and acti
Page 131 and 132:
0340 ALTERED FIBRIN CLOT STRUCTURE
Page 133 and 134:
Conclusions. This study demonstrate
Page 135 and 136:
0354 FACTOR V LEIDEN HOMOZYGOUS GEN
Page 137 and 138:
Results. From July 2005 through Mar
Page 139 and 140:
0364 CLINICAL EFFICACY OF OXALIPLAT
Page 141 and 142:
one marrow and peripheral blood ste
Page 143 and 144:
ecently suggested (Boissel et al.,
Page 145 and 146:
0378 SAFETY AND EFFICACY OF THE TER
Page 147 and 148:
Cytogenetics and molecular diagnost
Page 149 and 150:
0385 CYTOPLASMIC MUTATED NUCLEOPHOS
Page 151 and 152:
0390 ELTROMBOPAG RAISES PLATELET CO
Page 153 and 154:
factor for the achievement of CR wa
Page 155 and 156:
The cases of RAS showed two peaks o
Page 157 and 158:
is 85%. Seven out of the 25 relapse
Page 159 and 160:
0409 FRACTIONATED RADIOIMMUNOTHERAP
Page 161 and 162:
0414 COMPARATIVE ANALYSIS OF THE CO
Page 163 and 164:
successfully managed with GM-CSF di
Page 165 and 166:
49% for PCR positive patients (95%
Page 167 and 168:
+8 (1 PR+1 HI) and 14/24 pts with c
Page 169 and 170:
(e.g. bcr-abl leading to CML). CSC
Page 171 and 172:
0438 TERC MUTATIONS ANALYSIS IN PAT
Page 173 and 174:
observed in all mice. Analysis of l
Page 175 and 176:
ex-vivo expansion of HUCB-derived H
Page 177 and 178:
ic kidney disease in univariate or
Page 179 and 180:
One hundred eleven CN AML patients,
Page 181 and 182:
to asses intestinal epithelial dama
Page 183 and 184:
genesis of acute myeloid leukaemia
Page 185 and 186:
polymorphism at nucleotide 4889 of
Page 187 and 188:
expression along with a decreased C
Page 189 and 190:
0487 MUTATIONAL STATUS OF NUCLEOPHO
Page 191 and 192:
previously reported, a single cours
Page 193 and 194:
0497 SINGLE AGENT CLORETAZINE (VNP4
Page 195 and 196:
ly received melphalan-based chemoth
Page 197 and 198:
were similar among the 3 groups. Ho
Page 199 and 200:
Methods. Several read-out systems w
Page 201 and 202:
0518 SERUM AND CELLULAR EXPRESSION
Page 203 and 204:
0523 DNA REPAIR INHIBITION IN RESTO
Page 205 and 206:
held true when BMI-1 expression was
Page 207 and 208:
Ph + cells in the bone marrow). We
Page 209 and 210:
derivative chromosome (4p16, 7p14,
Page 211 and 212:
0545 STABILIZED BONE MARROW IS NOT
Page 213 and 214:
obtained in low (Sokal) risk patien
Page 215 and 216:
median dose intensity being 800 (21
Page 217 and 218:
from pivotal clinical trials. Metho
Page 219 and 220:
Cytogenetics and Molecular diagnost
Page 221 and 222:
to set up and optimize a D-HPLC-bas
Page 223 and 224:
0576 WESTERN BLOT IDENTIFICATION OF
Page 225 and 226:
Basic disease was AML (n=5), ALL (n
Page 227 and 228:
0588 EXTRACORPOREAL PHOTOPHORESIS F
Page 229 and 230:
acquire a cytolytic capacity agains
Page 231 and 232:
informed vignettes describing healt
Page 233 and 234:
using CHOP-21 in the UK, pegfilgras
Page 235 and 236:
0609 SOFT TISSUE COMPLICATIONS IN P
Page 237 and 238:
inding lectin (MBL) gene by polymer
Page 239 and 240:
all infection rate (p=0.12) as well
Page 241 and 242:
Myelodysplastic syndromes II 0623 M
Page 243 and 244:
formation (in total 28 samples). Ti
Page 245 and 246:
sion. In addition, confocal analysi
Page 247 and 248:
Myeloproliferative disorders - Clin
Page 249 and 250:
open-label, multi-centre study enro
Page 251 and 252:
iopsies after 6 and 12 months treat
Page 253 and 254:
Myeloproliferative disorders Chroni
Page 255 and 256:
ash, muscolar cramps, diarrhoea, he
Page 257 and 258:
induced significant apoptosis (mean
Page 259 and 260:
Myeloma and other monoclonal gammop
Page 261 and 262:
the therapy of choice for POEMS is
Page 263 and 264:
er patient does not indicate such t
Page 265 and 266:
Myeloma and other monoclonal gammop
Page 267 and 268:
secutive patients with MM, referred
Page 269 and 270:
whether gene expression values may
Page 271 and 272:
0705 THE SHIFT OF TREATMENT FOR NAS
Page 273 and 274:
0710 CLINICO-PATHOLOGICAL FEATURES,
Page 275 and 276:
patients presented a stage IV disea
Page 277 and 278:
plete remission or recurrent diseas
Page 279 and 280:
known at NHL diagnosis, were includ
Page 281 and 282:
0731 THE IMPACT OF HIV ON NON-HODGK
Page 283 and 284:
patients had died of their underlyi
Page 285 and 286:
scripts and proteins most affected
Page 287 and 288:
modulated after 24 h (37 up- and 59
Page 289 and 290:
0753 A SUSTAINED REMISSION OF IDIOP
Page 291 and 292:
and treatment, has rarely been syst
Page 293 and 294:
uncontrolled massive bleeding affec
Page 295 and 296:
Results. A total of 396 patients we
Page 297 and 298:
C30 questionnaire, and the correspo
Page 299 and 300:
wave length of light of reflected r
Page 301 and 302:
0783 PREVALENCE OF MEMBRANE PROTEIN
Page 303 and 304:
erozygous mother has a more severe
Page 305 and 306:
0794 CARDIAC MANIFESTATIONS IN A BR
Page 307 and 308:
0799 INEFFECTIVE ERYTHROPOIESIS IN
Page 309 and 310:
p=0.014 and p=0.003, respectively).
Page 311 and 312:
0809 CURRENT APPROACH TO CHELATION
Page 313 and 314:
Thrombosis II 0814 UNSUSPECTED PULM
Page 315 and 316:
the 97.5th percentile (5.2 U/mL) ge
Page 317 and 318:
symptoms of DVT, 3 (7.89%) previous
Page 319 and 320:
Transfusion medicine and vascular b
Page 321 and 322:
tions (most bacterial, 2 malaria, 6
Page 323 and 324:
0844 INCREASED LEUKOCYTE-PLATELET I
Page 325 and 326:
0851 CORD BLOOD DERIVED MESENCHYMAL
Page 327 and 328:
SIMULTANEOUS SESSION II Chronic mye
Page 329 and 330:
0862 COMPARISON OF DASATINIB TO HIG
Page 331 and 332:
0867 COMPREHENSIVE GERIATRIC ASSESS
Page 333 and 334:
0872 MN1 INDUCES LEUKEMIA IN MICE A
Page 335 and 336:
0877 PAX5/TEL TRANSDUCED PRE-BI CEL
Page 337 and 338:
0882 CISPLATIN INDUCES THROMBIN GEN
Page 339 and 340:
have an early manifestation of typi
Page 341 and 342:
0892 INTEGRATION OF GENOME WIDE SNP
Page 343 and 344:
0897 THE PHENOTYPE OF JAK2V617F MUT
Page 345 and 346:
gest diverse sequences of NPM mutan
Page 347 and 348:
2004 to January, 2006. At enrollmen
Page 349 and 350:
with a p value of ≥ 0.10. Sets of
Page 351 and 352:
BRIC 126 and 4N1K) in cells lacking
Page 353 and 354:
sclerosis[NS] and 12 Mixed cellular
Page 355 and 356:
0927 MK-0457, A NOVEL MULTIKINASE I
Page 357 and 358:
Publication Only 0933 CLINICAL FEAT
Page 359 and 360:
HSCT from the available Asian as we
Page 361 and 362:
that the incidence of JAK2 mutation
Page 363 and 364:
without type 2 diabetes. Methods. T
Page 365 and 366:
pts (38.8%) that were isolated (abs
Page 367 and 368:
y using the Miltenyi CD34 isolation
Page 369 and 370:
0969 COMPARISON OF CD25 IMMUNOHISTO
Page 371 and 372:
cytes was 24 days (range 8-32 days)
Page 373 and 374:
a cytogenetic hallmark for M4/M5 su
Page 375 and 376:
normal human BM B progenitor cells
Page 377 and 378:
0994 INCIDENCE OF INVASIVE ASPERGIL
Page 379 and 380:
3 of disease relapse.TRM at day+100
Page 381 and 382:
survival of five years. This dismal
Page 383 and 384:
1011 FLOW CYTOMETRIC DNA INDEX AND
Page 385 and 386:
1018 THE EFFECT OF THE SUGARBAKER P
Page 387 and 388:
1024 KIR/HLA CLASS I MISMATCHING AN
Page 389 and 390:
ment details and thrombotic histori
Page 391 and 392:
1036 INCIDENCE AND SPECTRUM OF INFE
Page 393 and 394:
tinely by our stem cell lab prior t
Page 395 and 396:
tion to a translocation t(5;14)(q35
Page 397 and 398:
ment of CML and induces a high rate
Page 399 and 400:
due to reactivation and/or progress
Page 401 and 402:
1063 ABNORMAL METHYLATION STATUS OF
Page 403 and 404:
1069 CLINICAL RELEVANCE OF REGULATO
Page 405 and 406:
1076 SERUM LEVELS OF SOLUBLE HLA CL
Page 407 and 408:
patient is still undergoing intensi
Page 409 and 410:
nificant MVD differences were detec
Page 411 and 412:
dictor of OS (p=0.004). High dose t
Page 413 and 414:
1099 ALTERATIONS IN THE NATURAL KIL
Page 415 and 416:
1105 CYTOGENETIC ABNORMALITIES IN 3
Page 417 and 418:
1110 CONSTITUTIVE ACTIVATION OF STA
Page 419 and 420:
efficacy results with a well-tolera
Page 421 and 422:
unmutated VH genes, and high and lo
Page 423 and 424:
Aims. Aim of this study was to pred
Page 425 and 426:
tested across a wide range of human
Page 427 and 428:
were incidentally diagnosed (52%).
Page 429 and 430:
ß2GP1 may be considered as determi
Page 431 and 432:
characterized in 198 β thalassaemi
Page 433 and 434:
1155 PLATELET AGGREGATION IN CHILDR
Page 435 and 436:
to-pelvic or perineal trauma. No me
Page 437 and 438:
in age. High prevalence of LBM amon
Page 439 and 440:
ecause some of the patients were or
Page 441 and 442:
of the drug is crucial to allow lon
Page 443 and 444:
egarding cost analysis of ASCT in G
Page 445 and 446:
ID Allo-BMT, 1 family one mismatche
Page 447 and 448:
admitted to ICU were discharged des
Page 449 and 450:
events -Postoperative states: 9,19%
Page 451 and 452:
efficacy and decreased atherosclero
Page 453 and 454:
1217 INCIDENCE OF EARLY STAGE IDIOP
Page 455 and 456:
1691GA and 1 homozygous 1691AA. The
Page 457 and 458:
1230 ASSOCIATION OF HEPARANASE GENE
Page 459 and 460:
posed, was: DF = (CD43%+FMC7%+CD79b
Page 461 and 462:
treatment of acute promyelocityc le
Page 463 and 464:
loaded group and 35 (70%) were non-
Page 465 and 466:
mild. Fas and soluble Fas ligand le
Page 467 and 468:
1265 POSACONAZOLE THERAPY IN REFRAC
Page 469 and 470:
ly express the cytoplasmic (inactiv
Page 471 and 472:
findings confirmed the significant
Page 473 and 474:
a less favorable prognosis. Interes
Page 475 and 476:
disease (HD), 4 patients (9%) with
Page 477 and 478:
1295 HEMOPHAGOCYTIC LYMPHOHYSTIOCYT
Page 479 and 480:
phamide 750 mg/m 2 on day 1, vincri
Page 481 and 482:
nomenon is unclear. It has been sug
Page 483 and 484:
oped mild thrombocytopenia (platele
Page 485 and 486:
gle dose of 54mg/m 2 rituximab furt
Page 487 and 488:
patients (pts), 36 male, with acute
Page 489 and 490:
esulting alterations of the endothe
Page 491 and 492:
(range 1-7) and 28,6% of patients h
Page 493 and 494:
three decades. In vivo, Ara-C is tr
Page 495 and 496:
statistical analysis. Results. Seve
Page 497 and 498:
Results. Though there was no recogn
Page 499 and 500:
2% and 19% of patients with or with
Page 501 and 502:
were older than 65 y) which can be
Page 503 and 504:
1376 RESVERATROL INDUCED P53 MEDIAT
Page 505 and 506:
median time of 21 days to reach >0.
Page 507 and 508: ly. Conclusions. 1. Combined intens
Page 509 and 510: to the presence of IVS1-6 mutation
Page 511 and 512: fy predictive factors for these abn
Page 513 and 514: acute leukemia. However, we cannot
Page 515 and 516: agents. They involve primarily the
Page 517 and 518: voriconazole for 2 months followed
Page 519 and 520: typed using a commercially availabl
Page 521 and 522: low up of ABL KD mutations’ level
Page 523 and 524: with development of BC/AP. 2. EVI-1
Page 525 and 526: 1447 THE IMPACT OF DISPARITY IN SHO
Page 527 and 528: three had visual field defects, two
Page 529 and 530: acquired mutation most prone to cau
Page 531 and 532: 1466 ROS GENERATION AND APOPTOSIS I
Page 533 and 534: 1473 DIARRHEIC SYNDROME, A CLINICAL
Page 535 and 536: gene fusion is an independent progn
Page 537 and 538: 1484 EPIDEMIOLOGY AND RESPONSE TO T
Page 539 and 540: 1492 FREQUENCY OF MEDITERRANEAN GLU
Page 541 and 542: immune globulin was administered at
Page 543 and 544: maintained on Imatinib 400 mg. Afte
Page 545 and 546: Hodgkin’s disease is well known,
Page 547 and 548: gram provided a unique chance to de
Page 549 and 550: even when ADP-induced plt activatio
Page 551 and 552: medullary involvement of multiple m
Page 553 and 554: 1540 ADMINISTRATION OF G-CSF AND CH
Page 555 and 556: 1548 QUALITY ANALYSIS OF THE MULTID
Page 557: Index of authors A Aapro, M., 0377,
Page 561 and 562: Bottini, P.V., 1181 Botto, B., 0408
Page 563 and 564: Chaidos, A., 0456, 0498, 0599, 0686
Page 565 and 566: De Keersmaecker, K., 0442, 0875 De
Page 567 and 568: El-Sharkawy, N., 0016 Elwahidi, G.,
Page 569 and 570: Garcia-Frade, J., 0346, 0680, 1105
Page 571 and 572: H Haas, N., 0742 Haas, O.A., 0001,
Page 573 and 574: Jaksic, B., 0127, 0446 Jaksic, O.,
Page 575 and 576: Körmöczi, G., 0848 Kornblau, S.,
Page 577 and 578: Lin, L.-I., 0030, 0484 Lin, T., 012
Page 579 and 580: Massé, A., 0249 Massó, P., 1287,
Page 581 and 582: Musto, P., 0254, 0401, 0422, 0569,
Page 583 and 584: Papadavid, E., 1442 Papageorgiou, E
Page 585 and 586: Probatova, N., 0704 Prochazka, V.,
Page 587 and 588: Rykavicin, O., 0504 Ryningen, A., 0
Page 589 and 590: Sirard, C., 0127, 0128 Sirigou, A.,
Page 591 and 592: Thiebaut, A., 0454 Thieblemont, C.,
Page 593 and 594: Vincenzi, C., 1060 Viniou, N.-A., 0
Page 595 and 596: Zouabi, H., 0503, 0999 Zoumbos, N.C
Page 597 and 598: 12 th Congress of the European Hema
Page 603: 12 th Congress of the European Hema
show all

12th Congress of the European Hematology ... - Haematologica

Create successful ePaper yourself

Delete template?

Save as template?